The mega pharmaceutical firm Pfizer and the German biotech company BioNTech collaborated to codevelop COVID-19 vaccine candidate in an unprecedented manner.
As per the interim report of an early phase trial, the vaccine is touted to elicit a robust immune response in healthy adults. As part of the examination, the vaccine was administered in 45 healthy individuals in the age group of 18-55 years.
The researchers stated about the vaccine candidate BNT162b1as an RNA vaccine that induces an immune response by simulating the mRNA molecule utilised for the novel coronavirus SARS-CoV-2 to develop its infectious proteins.
Based on the research report, the vaccine candidate is designed to be delivered intramuscularly, which facilitates human cells to release protein part of the SARS-CoV-2 receptor-binding domain, where the immune system is trained to produce antibodies against it.
Researchers said that volunteers in the 10-g and 30-g groups were administered a second dose too on day 21. Although, the scientists observed mild to moderate side effects of the vaccine candidate, they claimed that the antibodies for covid-19 has developed within 21 days and hoped that it would lay a path in bringing a pioneering change in the vaccine development.